Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages

被引:207
作者
Boven, LA
van Meurs, M
Boot, RG
Mehta, A
Boon, L
Aerts, JM
Laman, JD
机构
[1] Erasmus MC, Dept Immunol, NL-3000 DR Rotterdam, Netherlands
[2] MS Ctr ErasMS, Dept Immunol, Rotterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands
[4] Royal Free Hosp, Royal Free Hosp & Univ Coll Sch Med, Dept Hematol, London NW3 2QG, England
[5] Macrozyme BV, Amsterdam, Netherlands
关键词
Gaucher disease; immunohistochemistry; alternatively activated macrophages; cytokines; mannose receptor;
D O I
10.1309/BG5VA8JRDQH1M7HN
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Although the existence of anti-inflammatory alternatively activated macrophages (aamphi) has been accepted widely based on in vitro studies, their in. vivo location, phenotype, and function still are debated. Gaucher disease (GD) is caused by a genetic deficiency in the lysosomal enzyme glucocerebrosidase and is characterized by accumulation of glycosphingolipids in so-called Gaucher cells (GO). By using immunohistochemical analysis we investigated whether this results in an aamphiphenotype. GCs are macrophage-like cells, expressing acid phosphatase, CD68, CD14, and HLA class II, but not CD11b, CD40, or dendritic cell markers. GCs show infrequent immunoreactivity for mannose receptor: GCs did not express proinflammatory cytokines such as tumor necrosis factor alpha and monocyte chemoattractant protein 1, but did express the aamphi markers CD163, CCL18, and interleukin-1 receptor antagonist. Furthermore. CD36 and signal receptor protein. alpha, involved in lipid uptake, also were observed on GCs. Thus, GCs represent a distinctive population of myeloid cells that resemble aamphi but differ from previously described in vitro aamphi.
引用
收藏
页码:359 / 369
页数:11
相关论文
共 44 条
[1]  
Allen MJ, 1997, QJM-MON J ASSOC PHYS, V90, P19
[2]   Decreased inducibility of TNF expression in lipid-loaded macrophages [J].
Ares M.P.S. ;
Stollenwerk M. ;
Olsson A. ;
Kallin B. ;
Jovinge S. ;
Nilsson J. .
BMC Immunology, 3 (1)
[3]  
Barak V, 1999, EUR CYTOKINE NETW, V10, P205
[4]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE [J].
BARTON, NW ;
BRADY, RO ;
DAMBROSIA, JM ;
DIBISCEGLIE, AM ;
DOPPELT, SH ;
HILL, SC ;
MANKIN, HJ ;
MURRAY, GJ ;
PARKER, RI ;
ARGOFF, CE ;
GREWAL, RP ;
YU, KT .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) :1464-1470
[5]  
Beutler E., 1995, METABOLIC MOL BASES, P2641
[6]  
Bogoeva Biljana, 2001, Acta Medica Croatica, V55, P131
[7]   CLONING OF A CDNA-ENCODING CHITOTRIOSIDASE, A HUMAN CHITINASE PRODUCED BY MACROPHAGES [J].
BOOT, RG ;
RENKEMA, GH ;
STRIJLAND, A ;
VANZONNEVELD, AJ ;
AERTS, JMFG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (44) :26252-26256
[8]   Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention [J].
Boot, RG ;
Verhoek, M ;
de Fost, M ;
Hollak, CEM ;
Maas, M ;
Bleijlevens, B ;
van Breemen, MJ ;
van Meurs, M ;
Boven, LA ;
Laman, JD ;
Moran, MT ;
Cox, TM ;
Aerts, JMFG .
BLOOD, 2004, 103 (01) :33-39
[9]   MODIFYING EXOGENOUS GLUCOCEREBROSIDASE FOR EFFECTIVE REPLACEMENT THERAPY IN GAUCHER DISEASE [J].
BRADY, RO ;
MURRAY, GJ ;
BARTON, NW .
JOURNAL OF INHERITED METABOLIC DISEASE, 1994, 17 (04) :510-519
[10]  
Brooke GP, 1998, EUR J IMMUNOL, V28, P1, DOI 10.1002/(SICI)1521-4141(199801)28:01&lt